Jaen Juan C. 4

What Happened
Juan C. Jaen, President of Arcus Biosciences (RCUS), reported open-market sales totaling 68,569 shares across transactions on July 9–10, 2026. The three reported dispositions were: 48,502 shares at a weighted average $30.05 ($1,457,631), 19,799 shares at a weighted average $28.61 ($566,410), and 268 shares at a weighted average $29.40 ($7,878). Total proceeds were about $2.03 million. These were sales (not purchases) and were made pursuant to a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction dates: July 9, 2026 (48,502 sh @ $30.05); July 10, 2026 (19,799 sh @ $28.61 and 268 sh @ $29.40).
• Total shares sold: 68,569; approximate total proceeds: $2,031,919.
• Price ranges (per footnotes): first sale prices ranged $29.86–$30.57; second sale $28.17–$29.01; third sale $29.30–$29.46. Reported prices are weighted averages; detailed per-share-price breakdowns are available upon request per the filing.
• Footnotes: sales were effected under a Rule 10b5-1 trading plan (F1). Holdings reported in the filing include unvested RSUs (F5).
• Filing: Form 4 was filed July 13, 2026 reporting the July 9–10 transactions; the filing does not indicate a late report.

Context

• These were planned open-market sales under a 10b5-1 plan, which are commonly used by insiders to sell shares on a pre-set schedule and are generally considered routine.
• Sales do not necessarily indicate the insider’s view of the company’s prospects; they report liquidity transactions rather than new investment.